

Special Issue

Antibiotic Synthesis, 2nd Edition

Message from the Guest Editors

The emergence of multidrug-resistant bacteria threatens the effectiveness of current antibiotics.

Bacteria continue to evolve at a rate that surpasses drug development, highlighting a necessity for new drugs with mechanisms that inhibit resistance development.

Furthermore, this situation is exacerbated by a reduction with the development of novel antibiotics. Potential strategies to overcome this dilemma are below: 1)

Discovery of new antimicrobial agents from natural sources and their synthetic derivatives;

2) The design and synthesis of antimicrobial compounds with novel mechanisms of action;

3) Targeted delivery of antimicrobial agents;

4) Combination therapy involving antibiotics and new antimicrobial agents;

5) Synthesis of dual- and multi-action antibiotics;

6) Synthesis of adjuvants to enhance the potency of antibiotics;

7) Exploiting innate bacterial responses to develop new antibiotics. The Special Issue will publish contemporary research on the discovery and development of new classes of antibiotic compounds, dual-action antimicrobials and other combination strategies. It is my pleasure to invite submissions of high-quality research-based papers related to the topics.

Guest Editors

Prof. Dr. Naresh Kumar

School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia

Dr. Tsz Tin Yu

School of Chemistry, University of New South Wales (UNSW Sydney), Sydney, NSW 2052, Australia

Deadline for manuscript submissions

31 March 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/240312

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)